However, this traditional TNM staging system is insufficient for predicting breast cancer patients’ survival because it omits important biological factors, such as hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) status, which have significant impact on survival. This evidence concerns the gene ERBB2 and breast cancer.